Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling

Biomedicine and Pharmacotherapy

Volumn 67, Issue 5, 2013, Pages 351-356

  Gao, Zhenzhen ^a   Chen, Wei ^b   Zhang, Xiaohua ^a   Cai, Peifen ^a   Fang, Xianying ^b   Xu, Qiang ^b   Sun, Yang ^b   Gu, Yanhong ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Icotinib; PDK1, AKT; Squamous cell carcinoma

Indexed keywords

ALPHA3 INTEGRIN; ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ICOTINIB; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; UPREGULATION; UTERINE CERVIX CANCER; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CROWN ETHERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HUMANS; MICE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84878347943     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.03.012     Document Type: Article

References (35)

1. Christenson L.J., Borrowman T.A., Vachon C.M., Tollefson M.M., Otley C.C., Weaver A.L., et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005, 294:681-690.
2. Kanazawa N., Moriyama M., Onizuka T., Sugawara K., Mori S. Expression of bcl-6 protein in normal skin and epidermal neoplasms. Pathol Int 1997, 47:600-607.
3. Smith H.O., Tiffany M.F., Qualls C.R., Key C.R. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study. Gynecol Oncol 2000, 78:97-105.
4. Bhatt A.N., Mathur R., Farooque A., Verma A., Dwarakanath B.S. Cancer biomarkers - current perspectives. Indian J Med Res 2010, 132:129-149.
5. Nouri K., Rivas M.P., Pedroso F., Bhatia R., Civantos F. Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma of the head and neck. Arch Dermatol 2004, 140:1284.
6. Maubec E., Petrow P., Scheer-Senyarich I., Duvillard P., Lacroix L., Gelly J., et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011, 29:3419-3426.
7. Vokes E. Current treatments and promising investigations in a multidisciplinary setting. Ann Oncol 2005, 16(Suppl. 6):vi25-vi30.
8. Desai C. Squamous cell carcinoma of the head and neck region: insights from the American Society of Clinical Oncology 2008 presentations. Indian J Cancer 2008, 45:90-92.
9. Cranmer L.D., Engelhardt C., Morgan S.S. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist 2010, 15:1320-1328.
10. Ren G.J., Zhao Y.Y., Zhu Y.J., Xiao Y., Xu J.S., Shan B., et al. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer. Chin Med J (Engl) 2011, 124:19-25.
11. Zhao Q., Shentu J., Xu N., Zhou J., Yang G., Yao Y., et al. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 2011, 73:195-202.
12. Liu D., Jiang J., Hu P., Tan F., Wang Y. Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:3781-3786.
13. Tan F., Shen X., Wang D., Xie G., Zhang X., Ding L., et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 2012, 76:177-182.
14. Valster A., Tran N.L., Nakada M., Berens M.E., Chan A.Y., Symons M. Cell migration and invasion assays. Methods 2005, 37:208-215.
15. Qian F., Zhang Z.C., Wu X.F., Li Y.P., Xu Q. Interaction between integrin alpha(5) and fibronectin is required for metastasis of B16F10 melanoma cells. Biochem Biophys Res Commun 2005, 333:1269-1275.
16. Sun Y., Wu X.X., Yin Y., Gong F.Y., Shen Y., Cai T.T., et al. Novel immunomodulatory properties of cirsilineol through selective inhibition of IFN-gamma signaling in a murine model of inflammatory bowel disease. Biochem Pharmacol 2010, 79:229-238.
17. Nunez R. DNA measurement and cell cycle analysis by flow cytometry. Curr Issues Mol Biol 2001, 3:67-70.
18. Wang L., Gu Y., Shu Y., Shen Y., Xu Q. Integrin alpha6(high) cell population functions as an initiator in tumorigenesis and relapse of human liposarcoma. Mol Cancer Ther 2011, 10:2276-2286.
19. Perez-Tenorio G., Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002, 86:540-545.
20. Vatish M., Tesfa L., Grammatopoulos D., Yamada E., Bastie C.C., Pessin J.E. Inhibition of Akt activity and calcium channel function coordinately drive cell-cell fusion in the BeWO choriocarcinoma placental cell line. PLoS One 2012, 7:e29353.
21. Bos J.L. A target for phosphoinositide 3-kinase: Akt/PKB. Trends Biochem Sci 1995, 20:441-442.
22. Ding Z., Liang J., Li J., Lu Y., Ariyaratna V., Lu Z., et al. Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. PLoS One 2010, 5:e9910.
23. Yang G., Yao Y., Zhou J., Zhao Q. Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer. Oncol Rep 2012, 27:2066-2072.
24. Foo C.C., Lee J.S., Guilanno V., Yan X., Tan S.H., Giam Y.C. Squamous cell carcinoma and Bowen's disease of the skin in Singapore. Ann Acad Med Singapore 2007, 36:189-193.
25. Massari L.P., Kastelan M., Gruber F. Epidermal malignant tumors: pathogenesis, influence of UV light and apoptosis. Coll Antropol 2007, 31(Suppl. 1):83-85.
26. Fenouille N., Puissant A., Tichet M., Zimniak G., Abbe P., Mallavialle A., et al. SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. Oncogene 2011, 30:4887-4900.
27. Vincent E.E., Elder D.J., Thomas E.C., Phillips L., Morgan C., Pawade J., et al. Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br J Cancer 2011, 104:1755-1761.
28. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998, 10:262-267.
29. Hotfilder M., Sondermann P., Senss A., van Valen F., Jurgens H., Vormoor J. PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death. Br J Cancer 2005, 92:705-710.
30. Wei M., Liu B., Gu Q., Su L., Yu Y., Zhu Z. Stat6 cooperates with Sp1 in controlling breast cancer cell proliferation by modulating the expression of p21(Cip1/WAF1) and p27 (Kip1). Cell Oncol (Dordr) 2012.
31. Donjerkovic D., Scott D.W. Regulation of the G1 phase of the mammalian cell cycle. Cell Res 2000, 10:1-16.
32. Schmidt M., Hovelmann S., Beckers T.L. A novel form of constitutively active farnesylated Akt1 prevents mammary epithelial cells from anoikis and suppresses chemotherapy-induced apoptosis. Br J Cancer 2002, 87:924-932.
33. McLeod H.L., Brunton V.G., Eckardt N., Lear M.J., Robins D.J., Workman P., et al. In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022. Br J Cancer 1996, 74:1714-1718.
34. Xia W., Mullin R.J., Keith B.R., Liu L.H., Ma H., Rusnak D.W., et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002, 21:6255-6263.
35. Prewett M.C., Hooper A.T., Bassi R., Ellis L.M., Waksal H.W., Hicklin D.J. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002, 8:994-1003.